Filing Flows › Comparisons › MRNA vs NBIX
Moderna vs Neurocrine Biosciences: MRNA and NBIX compared
Moderna is the larger company: $1.3B of revenue in its latest quarter (Q3 2026) against $1.1B for Neurocrine Biosciences (Q3 2026). Neurocrine Biosciences is growing faster (+41% against +29% a year earlier). Neurocrine Biosciences is more profitable, with an operating margin of 29.5% against 9.9%.
Where the money goes: MRNA and NBIX
Moderna (MRNA) · Q3 2026
Moderna, Q3 2026: revenue $1.3B (+29% year over year), operating margin 9.9%, net earnings $162M, operating cash flow −$1.6B. The chart follows the revenue to costs, profit and cash.
Neurocrine Biosciences (NBIX) · Q3 2026
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
| Moderna (MRNA) | Neurocrine Biosciences (NBIX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.3B | $1.1B |
| Revenue growth, Y/Y | +29% | +41% |
| Operating margin | 9.9% | 29.5% |
| Net earnings | $162M | $206M |
| Net margin | 12.3% | 18.4% |
| Operating cash flow | −$1.6B | $395M |
| Free cash flow | — | $384M |
| Market value | $109.3B | $17.3B |
| P/E | — | 24.4× |
| Analysts’ mean target | $145.42 | $208.11 |
Where the revenue comes from
Moderna
- Net product sales: $1.3B (97%)
- RSV: $29.0M (2%)
- Collaboration Arrangement, Including Arrangements with Affiliate: $8.0M (1%)
Questions
Which is bigger, Moderna or Neurocrine Biosciences?
Moderna is the larger company: $1.3B of revenue in its latest quarter (Q3 2026) against $1.1B for Neurocrine Biosciences (Q3 2026).
Is Moderna or Neurocrine Biosciences growing faster?
Neurocrine Biosciences is growing faster (+41% against +29% a year earlier).
Which is more profitable, Moderna or Neurocrine Biosciences?
Neurocrine Biosciences is more profitable, with an operating margin of 29.5% against 9.9%.
More: Moderna earnings · how Moderna makes money · Neurocrine Biosciences earnings · how Neurocrine Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.